500 Unicorn Park Drive
Suite 303
Woburn, MA 01801
United States
781 222 9600
https://www.replimune.com
Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 284
Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
---|---|---|---|---|
Mr. Philip Astley-Sparke F.S.A. | Executive Chairman | 1,01M | N/A | 1971 |
Dr. Sushil Patel Ph.D. | Chief Executive Officer | 623,51k | N/A | 1971 |
Dr. Robert Coffin Ph.D. | Founder, Chief Scientist & Director | 736,8k | N/A | 1965 |
Ms. Emily Luisa Hill | Chief Financial Officer | N/A | N/A | 1980 |
Mr. Andrew Schwendenman | Chief Accounting Officer & Treasurer | N/A | N/A | 1976 |
Mr. Christopher Sarchi | Chief Commercial Officer | N/A | N/A | 1968 |
Dr. Konstantinos Xynos M.B.A., M.D., Ph.D. | Chief Medical Officer | N/A | N/A | 1966 |
Mr. Paul Bullock | Chief Manufacturing Officer & Framingham Site Head | N/A | N/A | N/A |
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Replimune Group, Inc.s ISS Governance QualityScore, Stand 29. April 2024, lautet 7. Die grundlegenden Scores sind Audit: 7, Vorstand: 6, Shareholderrechte: 8, Kompensation: 7.